Anti-Abeta active immunotherapy
Alzheimer's Disease (Prevention)
Phase 2Licensed to Takeda - Option and license agreement signed 2024
Key Facts
Indication
Alzheimer's Disease (Prevention)
Phase
Phase 2
Status
Licensed to Takeda - Option and license agreement signed 2024
Company
About AC Immune
AC Immune's mission is to diagnose, treat, and prevent neurodegenerative diseases through a precision medicine approach. The company has achieved significant validation through high-value partnerships with major pharmaceutical firms like Takeda, Janssen, and Lilly, and its pipeline features promising Phase 2 candidates in Alzheimer's and Parkinson's disease. Its strategy balances internal R&D of first- and best-in-class candidates with strategic collaborations that provide non-dilutive funding and de-risk development.
View full company profileTherapeutic Areas
Other Alzheimer's Disease (Prevention) Drugs
| Drug | Company | Phase |
|---|---|---|
| Preventative Vaccine | Abyssinia Biologics | Preclinical |